Physician profile
Cassandra Edwards
NPI 1649348871
$1,894.22
in general payments reported to CMS, 2019-2025
17 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $185 · 2023: $889 · 2024: $535 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.95 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $312.25 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $247.29 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $241.28 | 2022-2023 | Wegovy |
| Glaxosmithkline, LLC. | $174.86 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $122.76 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $86.19 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $69.96 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.87 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.42 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $43.65 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.66 | 2024 | Caplyta |
| Sanofi-Aventis U.S. LLC | $24.11 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $22.95 | 2025 | Neffy |
| Dexcom, INC. | $22.39 | 2023 | Dexcom G6 Transmitter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $17.37 | 2024 | Gvoke Hypopen |
| Amgen INC. | $14.26 | 2023 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.